Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksParagon Group Regulatory News (PAG)

Share Price Information for Paragon Group (PAG)

Share Price is delayed by 15 minutes
Get Live Data
779.00    -13.00 (-1.64%)
Bid:
779.00
Ask:
779.50
Spread: 0.50 (0.064%)
Market Cap: £1.44b
PAG Live PriceLast checked at - London Stock Exchange

Intraday Paragon Group Share Chart

Trading Update

24 Jan 2025 07:00

RNS Number : 5137U
Paragon Banking Group PLC
24 January 2025
 

RNS ANNOUNCEMENT

24 January 2025

 

PARAGON BANKING GROUP PLC

Trading update

POSITIVE START TO FY25: FULL YEAR GUIDANCE REITERATED

 

Paragon Banking Group PLC ("the Group" or "Paragon") today publishes its trading update based on the business performance from 1 October to 31 December 2024.

The Group's trading performance has been in line with the Board's expectations for the first quarter of its 2024/25 financial year and all elements of full year guidance are reiterated.

Nigel Terrington, Chief Executive, said:

"The first quarter of our new financial year has continued to see good progress with encouraging new business flows and margins running above expectations. The benefits of our digitalisation programme remain evident in both demand and efficiency, and we will roll-out further technology-driven changes during 2025. The Group remains confident in the guidance given for the full year and our strong capital levels mean we are well-positioned to continue delivering strong returns for our shareholders and further support for customers."

Operational highlights

We have seen an encouraging start to the financial year with volumes in line with expectations and our net interest margin outperforming expectations. New lending across the business for the quarter to 31 December 2024 totalled £677.4 million compared to £610.7 million in 2024 Q1. Buy-to-let lending totalled £423.2 million (2024 Q1: £336.3 million). Commercial Lending advances were £254.2 million (2024 Q1: £274.4 million), the reduction being primarily a result of timing differences in our structured lending business with the other business lines performing strongly.

 

The Group's buy-to-let pipeline ended the quarter at £691.9 million, 23.6% above its position a year earlier (December 2023: £559.6 million). Within Development Finance, the value of both the new business pipeline and undrawn facilities rose during the quarter, with the 31 December levels up 33.5% and 16.1% for the two measures respectively when compared to the December 2023 position.

 

Buy-to-let redemptions reflected an annualised redemption rate of 7.7% (2024 Q1: 6.4%), reflecting continued strong retention levels.

 

The portfolio continues to perform strongly, with BTL three month plus arrears 13 basis points lower than their December 2023 level at 44 basis points.

 

The Group's net loan balances grew by 1.0% to £15.9 billion during the quarter (up 5.5% from the December 2023 level) maintaining the growth rate seen for FY24.

 

 

Capital and funding

 

With the bulk of TFSME refinancing completed during FY24, deposit growth has been more aligned to the rate of loan book growth, increasing by 0.9% in the quarter, supporting the Group's NIM performance.

 

Q1 saw the completion of the final £7.5 million of the 2024 share buy-back programme, with the 2025 buy-back, of up to £50 million, having commenced in Q2.

 

After allowing for half of an interim dividend in line with policy and the full 2025 buy-back, the Group's unverified CET1 and total capital ratios remain strong at 14.0% and 15.8% respectively.

 

The Group continues to make progress with the PRA on its buy-to-let IRB application and had made its application to access the Interim Capital Regime ("ICR") before the most recent announcement by the Bank of England, delaying the implementation of the Basel 3.1 rules. We expect to hear from the Bank of England shortly regarding what this delay means for the ICR and the broader range of consultations and initiatives they have underway regarding Bank capital requirements.

 

Guidance and outlook

 

The Board's FY25 guidance for net interest margin, new business volumes, operating costs and RoTE remain unchanged, although margins are currently running ahead of expectations.

 

FY25 guidance summary

Volumes

Buy-to-let

Commercial

 

£1.6-£1.8 billion

£1.2-£1.4 billion

NIM

3% area

Opex

c£185 million

U/L RoTE

mid 15-20%

 

 

 

For further information, please contact:

 

Paragon Banking Group PLC

Headland 

Nigel Terrington, Chief ExecutiveRichard Woodman, Chief Financial Officer

Lucy Legh/Doug McDougall

paragon@headlandconsultancy.com

Tel: 0121 712 2505

Tel: 020 3805 4822

 

 

Paragon is expected to release its half-year results for the six months to 31 March 2025 on Wednesday 4 June 2025.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSESFMDEISELF
Date   Source Headline
27th Jan 20265:25 pmRNSTransaction in Own Shares
27th Jan 20267:00 amRNSTrading Update
26th Jan 20265:36 pmRNSTransaction in Own Shares
23rd Jan 20265:19 pmRNSTransaction in Own Shares
23rd Jan 202611:49 amRNS2025 Pillar III Disclosures
23rd Jan 202611:09 amRNSAnnual Financial Report
22nd Jan 20265:21 pmRNSTransaction in Own Shares
21st Jan 20265:20 pmRNSTransaction in Own Shares
20th Jan 20265:13 pmRNSTransaction in Own Shares
19th Jan 20265:26 pmRNSTransaction in Own Shares
16th Jan 20265:17 pmRNSTransaction in Own Shares
15th Jan 20265:12 pmRNSTransaction in Own Shares
14th Jan 20265:27 pmRNSTransaction in Own Shares
13th Jan 20265:19 pmRNSTransaction in Own Shares
12th Jan 20265:38 pmRNSTransaction in Own Shares
9th Jan 20265:15 pmRNSTransaction in Own Shares
8th Jan 20265:37 pmRNSTransaction in Own Shares
7th Jan 20265:17 pmRNSTransaction in Own Shares
6th Jan 20265:19 pmRNSTransaction in Own Shares
5th Jan 20265:28 pmRNSTransaction in Own Shares
2nd Jan 20268:30 amRNSTotal Voting Rights
19th Dec 20255:23 pmRNSTransaction in Own Shares
19th Dec 20255:23 pmRNSTransaction in Own Shares
18th Dec 20255:18 pmRNSTransaction in Own Shares
18th Dec 20255:18 pmRNSTransaction in Own Shares
17th Dec 20255:31 pmRNSTransaction in Own Shares
16th Dec 20255:38 pmRNSTransaction in Own Shares
15th Dec 20255:23 pmRNSTransaction in Own Shares
12th Dec 20255:23 pmRNSTransaction in Own Shares
11th Dec 20255:45 pmRNSTransaction in Own Shares
10th Dec 20255:43 pmRNSTransaction in Own Shares
9th Dec 20256:11 pmRNSTransaction in Own Shares
9th Dec 202511:27 amRNSDirector/PDMR Shareholding
8th Dec 20255:45 pmRNSTransaction in Own Shares
4th Dec 20252:46 pmRNSDirector/PDMR Shareholding
3rd Dec 20257:00 amRNSFinal Results
1st Dec 20255:00 pmRNSBlock listing Interim Review
1st Dec 20259:11 amRNSTotal Voting Rights
31st Oct 20255:15 pmRNSTotal Voting Rights
8th Oct 20259:05 amRNSHolding(s) in Company
3rd Oct 20251:16 pmRNSHolding(s) in Company
30th Sep 20255:35 pmRNSTotal Voting Rights
30th Sep 20255:28 pmRNSTransaction in Own Shares
30th Sep 20254:53 pmRNSHolding(s) in Company
29th Sep 20256:12 pmRNSTransaction in Own Shares
29th Sep 202512:18 pmRNSDirector/PDMR Shareholding
26th Sep 20255:17 pmRNSTransaction in Own Shares
25th Sep 20255:08 pmRNSTransaction in Own Shares
24th Sep 20255:25 pmRNSTransaction in Own Shares
23rd Sep 20255:12 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.